Literature DB >> 8604954

Lewy body disease and dementia. A review.

S Kalra1, C Bergeron, A E Lang.   

Abstract

Lewy bodies (LBs) are intracytoplasmic neuronal inclusions sometimes found in the brain stem, diencephalon, basal ganglia, and cerebral cortex. Cases designated as diffuse Lewy body disease (DLBD) demonstrate widespread cortical and subcortical Lewy body formation. The fact that DLBD is possibly the second most common cause of dementia after Alzheimer's disease is not generally recognized. We hope to emphasize the importance of this common neurodegenerative disorder by reviewing the literature and our own experience with DLBD. The English-language literature dealing with the clinical and pathological features of DLBD was reviewed. Pathological material from the Canadian Brain Tissue Bank, Toronto, Ontario, was reviewed over a 2-year period from 1991 through 1993. Prominent LB pathology may occur in isolation or mixed with pathological changes seen in Alzheimer's disease. Lewy body diseases include Parkinson's disease that presents with a classic movement disorder and sometimes dementia, and DLBD where LBs occur in a widespread distribution in the cortex in addition to the usual subcortical sites. Diffuse LB disease usually presents with a neurobehavioral syndrome that may include hallucinations, delusions, and psychosis; all patients eventually become demented. A day-to-day fluctuating mental state may be an important distinguishing clinical feature. Parkinsonism may follow the psychiatric disturbance although occasionally it is a presenting feature. Serious life- threatening side effects may occur with the use of standard neuroleptics. The variable clinical features and additional presence of Alzheimer-type pathological changes in many cases of DLBD has led to a confusing and inconsistent classification of LB disease and, together with little awareness of its existence, its misdiagnosis. Although DLBD may be the second most common cause of dementia, the terminology and classification of LB disorders and their relationship to Alzheimer's disease remain sources of intense debate. Further research is needed to resolve these issues and to provide insight into the pathogenesis of LB formation and accompanying neuronal degeneration.

Entities:  

Mesh:

Year:  1996        PMID: 8604954

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

Review 1.  Antipsychotic medications and the elderly: effects on cognition and implications for use.

Authors:  M J Byerly; M T Weber; D L Brooks; L R Snow; M A Worley; E Lescouflair
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Standardized Mini-Mental State Examination. Use and interpretation.

Authors:  A Vertesi; J A Lever; D W Molloy; B Sanderson; I Tuttle; L Pokoradi; E Principi
Journal:  Can Fam Physician       Date:  2001-10       Impact factor: 3.275

Review 3.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

Review 4.  Diffuse Lewy body disease: clinical, pathological, and neuropsychological review.

Authors:  C A Luis; W Mittenberg; C S Gass; R Duara
Journal:  Neuropsychol Rev       Date:  1999-09       Impact factor: 7.444

Review 5.  Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.

Authors:  Carole Parsons; Wei Yin Lim; Clement Loy; Bernadette McGuinness; Peter Passmore; Stephanie A Ward; Carmel Hughes
Journal:  Cochrane Database Syst Rev       Date:  2021-02-03

6.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand.

Authors:  Z Walker; D C Costa; R W H Walker; K Shaw; S Gacinovic; T Stevens; G Livingston; P Ince; I G McKeith; C L E Katona
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

7.  Comorbidity profile in dementia with Lewy bodies versus Alzheimer's disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry.

Authors:  Seyed-Mohammad Fereshtehnejad; Soheil Damangir; Pavla Cermakova; Dag Aarsland; Maria Eriksdotter; Dorota Religa
Journal:  Alzheimers Res Ther       Date:  2014-10-06       Impact factor: 6.982

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.